← Back to Search

Procedure

Physiotherapy for Lymphedema in Head and Neck Cancer Survivors

Phase 1
Waitlist Available
Led By John Rasmussen, PhD
Research Sponsored by The University of Texas Health Science Center, Houston
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights
No Placebo-Only Group

Summary

This trial will assess whether treating lymphatics in head and neck cancer survivors before diagnosis of lymphedema can prevent its development or progression.

Who is the study for?
This trial is for adults over 18 who've had head and neck cancer surgery and radiation, are within 3 months post-radiation but not pregnant or breastfeeding. They must agree to contraception use after imaging sessions, shave facial hair if male, and be able to use a compression device at home.
What is being tested?
The study tests if early physiotherapy can prevent lymphedema in head and neck cancer survivors. It uses near-infrared imaging to detect abnormal lymph flow and compares pneumatic compression therapy against standard care in preventing lymphatic dysfunction.
What are the potential side effects?
Potential side effects may include discomfort from the pneumatic compression device, skin irritation from shaving (for males), or reactions related to near-infrared imaging; however, specific side effects of these interventions are not detailed in the provided information.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Incidence/Severity of lymphedema
Secondary study objectives
Change in area of dermal lymphatic backflow

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Group I: No Dermal BackflowExperimental Treatment1 Intervention
Subjects who do not present with dermal lymphatic backflow at enrollment will be monitored at subsequent visits and if/when dermal lymphatic backflow is observed will be randomized into either Advanced Pneumatic Compression or Standard-of-Care arm.
Group II: Advanced Pneumatic CompressionExperimental Treatment2 Interventions
Subjects who present with dermal lymphatic backflow will be asked to complete a session of advanced pneumatic compression therapy each day at home.
Group III: Standard-of-CareActive Control1 Intervention
Subjects who present with dermal lymphatic backflow will continue under standard-of-care surveillance of lymphedema and will only receive treatment if they are diagnosed with head and neck cancer-acquired lymphedema.

Find a Location

Who is running the clinical trial?

The University of Texas Health Science Center, HoustonLead Sponsor
957 Previous Clinical Trials
347,837 Total Patients Enrolled
John Rasmussen, PhDPrincipal InvestigatorThe University of Texas Health Science Center, Houston
1 Previous Clinical Trials
11 Total Patients Enrolled

Media Library

Advanced pneumatic compression therapy (Procedure) Clinical Trial Eligibility Overview. Trial Name: NCT05937269 — Phase 1
Facial Lymphedema Research Study Groups: No Dermal Backflow, Advanced Pneumatic Compression, Standard-of-Care
Facial Lymphedema Clinical Trial 2023: Advanced pneumatic compression therapy Highlights & Side Effects. Trial Name: NCT05937269 — Phase 1
Advanced pneumatic compression therapy (Procedure) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05937269 — Phase 1
~2 spots leftby Feb 2025